0102030405
Sunitinib CAS No. 557795-19-4 Antineoplastic Pharmaceutical API
02
introduce
Sunitinib is a potent oral multi-targeted kinase inhibitor and core antineoplastic API, targeting VEGFR, PDGFR, KIT and other key receptors to inhibit tumor proliferation and angiogenesis. It is a first-line therapeutic for multiple malignant tumors.
Our product complying with strict international pharmaceutical standards to ensure high purity, stable efficacy and reliable supply for clinical treatment and pharmaceutical formulation.
02
Physical and chemical properties
Sunitinib possesses key physicochemical characteristics as follows:
- Melting Point: 189-191 °C
- Density: 1.2±0.1 g/cm³
- Boiling Point: 572.1±50.0 °C (Predicted)
- Flash Point: 299.8 °C
- Solubility: Slightly soluble in chloroform and methanol
- Storage Condition: 2-8 °C, sealed and protected from light
- Melting Point: 189-191 °C
- Density: 1.2±0.1 g/cm³
- Boiling Point: 572.1±50.0 °C (Predicted)
- Flash Point: 299.8 °C
- Solubility: Slightly soluble in chloroform and methanol
- Storage Condition: 2-8 °C, sealed and protected from light
Multi-targeted Antitumor Efficacy
As an multi-target tyrosine kinase inhibitor, it can act on multiple kinases related to tumor growth and angiogenesis. It can simultaneously achieve the dual effects of inhibiting tumor cell proliferation and blocking tumor blood supply, with more comprehensive treatment.
As an multi-target tyrosine kinase inhibitor, it can act on multiple kinases related to tumor growth and angiogenesis. It can simultaneously achieve the dual effects of inhibiting tumor cell proliferation and blocking tumor blood supply, with more comprehensive treatment.
Widely Applicable
Approved for the treatment of various malignant tumors, covering metastatic renal cell carcinoma, gastrointestinal stromal tumors and pancreatic neuroendocrine tumors, meeting diverse clinical treatment needs.
Drug Resistance Adaptability
It can be used for gastrointestinal stromal tumor patients who failed or could not tolerate imatinib treatment. Compared with similar drugs that cannot cope with drug resistance, it adapts to the treatment needs of more drug-resistant patients.
Gastrointestinal Stromal Tumor (GIST) Treatment
Used for gastrointestinal stromal tumor patients who failed or could not tolerate imatinib treatment, it controls tumor progression and relieves symptoms through dual antineoplastic effects.
Used for gastrointestinal stromal tumor patients who failed or could not tolerate imatinib treatment, it controls tumor progression and relieves symptoms through dual antineoplastic effects.
Renal Cell Carcinoma (RCC) Treatment
Used for the treatment of inoperable advanced or metastatic renal cell carcinoma, it inhibits tumor cell proliferation and angiogenesis, improves the patient's condition and delays disease progression.
Pancreatic Neuroendocrine Tumor (pNET) Treatment
Used for the treatment of pancreatic neuroendocrine tumors, it specifically inhibits tumor-related kinases, controls tumor growth and provides an effective treatment plan for patients.
Other Potential Applications in Research
It has been shown to have an inhibitory effect on various solid tumors such as lung cancer, liver cancer, breast cancer and glioma in animal experiments. Relevant clinical trials are underway, and its wider antineoplastic applications are also being explored.
We implement strict full-process quality inspection, with each batch of Sunitinib undergoing rigorous testing on key indicators such as purity, solubility and impurity content to meet standards. Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Equipped with a stable raw material supply chain, we ensure continuous large-scale supply of pharmaceutical grade Sunitinib.
Our professional technical team provides tailored services including pharmaceutical formulation optimization, clinical application guidance and post-sales technical support to meet the diverse needs of pharmaceutical enterprises, clinical institutions and research laboratories.
Our professional technical team provides tailored services including pharmaceutical formulation optimization, clinical application guidance and post-sales technical support to meet the diverse needs of pharmaceutical enterprises, clinical institutions and research laboratories.
As a classic multi-targeted antineoplastic API, Sunitinib has an irreplaceable core position in the clinical treatment of malignant tumors. It not only is a first-line therapeutic for multiple tumors but also provides an important research basis for the development of novel antitumor drugs. With stable product quality, reliable large-scale supply capacity and professional one-stop technical services, we are committed to providing high-quality Sunitinib API for global pharmaceutical companies, clinical medical institutions and biomedical research institutions, and supporting the development of tumor treatment and antineoplastic drug research.
Choose our Sunitinib to meet your application needs in pharmaceutical formulation, clinical treatment and biomedical research. Contact us for more product details and cooperation support.
Choose our Sunitinib to meet your application needs in pharmaceutical formulation, clinical treatment and biomedical research. Contact us for more product details and cooperation support.